CompletedPhase 1NCT02187445

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanderbilt University
Principal Investigator
Michael R DeBaun, MD, MPH, MD, MPH
Vanderbilt University Medical Center
Intervention
Budesonide inhalation suspension(drug)
Enrollment
36 enrolled
Eligibility
1-4 years · All sexes
Timeline
20142017

Study locations (1)

Collaborators

Emory University · Children's National Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02187445 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease

← Back to all trials